NEW YORK (GenomeWeb News) – Canadian molecular diagnostics company Rna Diagnostics has been chosen to have its breast cancer assay evaluated by the Toronto Health Economics and Technology Assessment initiative in a multi-center clinical trial, the company said on Thursday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.